インドのAPI(医薬品有効成分)市場機会

◆英語タイトル:Opportunities in Indian API Market
◆商品コード:RNCS51103
◆発行会社(リサーチ会社):RNCOS
◆発行日:2015年10月
◆ページ数:75
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:インド
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様利用)USD700 ⇒換算¥77,000見積依頼/購入/質問フォーム
Multi-UserUSD1,100 ⇒換算¥121,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

India, being the third largest API market in the Asia-Pacific region, has been gaining a lot of attention worldwide since the last few years. The accelerated growth of the Indian API market can be attributed to the increased efforts being made by the Indian government to improve the infrastructure of the API industry and provide maximum support to domestic API manufacturers. This is being done, so that India does not have to depend on other countries for the import of APIs. Indian API manufacturers are also trying to strengthen their hold of the regulated markets by various means. A major competitor for India in this field is China, which provides APIs at very low rates. However, all the hard work being put in by the API manufacturers and government will help India to become the top API market not only in Asia-Pacific, but also in the world.

In the report “Opportunities in Indian API Market”, RNCOS analysts have addressed the current scenario of the Indian API market, major drivers of the market, and factors hindering the growth of the market. Apart from this, the segmentation of the market by various parameters, such as type of manufacture, type of drug, type of API and type of therapeutic area, has also been specified. The important mergers and acquisitions in the Indian API market have also been mentioned in the report. Various initiatives taken by the government to promote the Indian API industry have been listed down. Owing to the various government initiatives, such as the declaration of 2015 as the “Year of APIs”, “Make in India” campaign, etc., the Indian API market is likely to show a promising growth in the coming years. The Indian API market is forecasted to grow at a CAGR of 13% from 2014-2020.

The report also mentions the key players in the Indian API Market. For every player, a brief business overview, geographic revenue break up, and segment wise revenue break up has been provided. A strength and weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of major players. A separate section has been provided in the report for the opportunities and recommendations for the development of the Indian API market. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Indian API market.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. India API Industry Outlook
3.1 Top 5 API Markets of the World
3.2 Share of India in Global API Market
3.3 Indian API Market Size (2009-2014)
3.4 Top 10 APIs in the Indian API Market
4. Drivers & Challenges
4.1 Drivers
4.1.1 Rising Healthcare Expenditure
4.1.2 Increasing Disposable Incomes
4.1.3 Rise in Geriatric Population
4.1.4 Increasing Incidences of Chronic Diseases
4.1.5 Patent Expiry of Blockbuster Drugs
4.1.6 Increased Consumption of Generic Drugs
4.1.7 Invention of New Generation of APIs
4.2 Challenges
4.2.1 Overdependence on China for Imports
4.2.2 Complex License Renewal Procedure
4.2.3 Few Manufacturers in the API Industry
4.2.4 Inadequate Infrastructure Facilities
4.2.5 Lack of Government Support
4.2.6 Stringent Regulatory Policies
5. Market Segmentation
5.1 By Type of Manufacturing
5.2 By Type of Drug
5.3 By Type of API
5.4 By Type of Therapeutic Area
6. Mergers and Acquisitions
7. Government Initiatives
7.1 Katoch Committee
7.2 ‘Make in India’ Campaign
7.3 Pharma Vision 2020
7.4 Establishment of New NIPERs
8. Regulatory Scenario
9. Competitive Landscape
9.1 Profiles
9.1.1 Sun Pharma
9.1.2 Cipla Limited
9.1.3 Biocon
9.1.4 Dr. Reddy’s Laboratories
9.1.5 Lupin Ltd.
9.1.6 Aurobindo Pharma Limited
9.1.7 Wockhardt
9.1.8 Zydus Cadila
9.1.9 Glenmark
9.1.10 Jubilant LifeSciences
10. Future Outlook
11. Opportunities and Recommendations

List of Figures:

Figure 3-1: India API Market Trade (%), 2009-2014
Figure 3-2: Top 5 API Markets of the World (%), 2014
Figure 3-3: Share of India in Global API Market (%), 2014
Figure 3-4: India API Market (Billion US$), 2009-2014
Figure 4-1: Healthcare Expenditure (% of GDP), 2009-2014
Figure 4-2: Personal Disposable Income (Billion US$), 2009-2014
Figure 4-3: Population Above 65 years (Million), 2009-2014
Figure 4-4: Diabetes Population in the Age Group 20-79 years (Million), 2013 & 2030
Figure 4-5: Number of Cancer Cases (‘000), 2014 & 2020
Figure 5-1: Share of Captive and Merchant Market APIs in Indian API Market (%), 2014
Figure 5-2: Share of Branded and Generic Drug APIs in Indian API Market (%), 2014
Figure 5-3: Share of Chemical/Small Molecule and Biotech APIs in Indian API Market (%), 2014
Figure 5-4: Share of APIs by their Application in Therapeutic Areas in Indian API Market (%), 2014
Figure 8-1: API License Procedure
Figure 9-1: Sun Pharma- Break up of Revenue by Therapeutic Segment (%), 2014
Figure 9-2: Sun Pharma- Break up of Revenue by Geography (%), 2014
Figure 9-3: Cipla Limited-Break up of Revenue by Geography (%), 2014
Figure 9-4: Biocon-Break up of Revenue by Geography (%), 2014
Figure 9-5: Dr. Reddy’s Laboratories – Break up of Revenue by Geography (%), 2014
Figure 9-6: Lupin Limited- Revenues by Trade (Billion US$), 2014
Figure 9-7: Aurobindo Pharma Limited – Break up of Revenue of Formulations by Geography (%), 2014
Figure 9-8: Wockhardt- Break up of Revenue by Geography (%), 2014
Figure 9-9: Zydus Cadila- Break up of Revenue by Geography (%), 2014
Figure 9-10: Glenmark- Break up of Revenue by Geography (%), 2014
Figure 9-11: Jubilant LifeSciences- Break up of Revenue by Geography (%), 2014
Figure 10-1: Indian API Market (Billion US$), 2015-2020

List of Tables:

Table 3-1: Top 10 APIs in the Indian API Market (2014)
Table 4-1: List of Blockbuster Drugs Losing Patent (2015-2020)
Table 4-2: API Import from China (2011-2015)
Table 6 1: Mergers and Acquisitions in Indian Pharma Industry (2014-2015)
Table 9-1: Sun Pharma- Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-2: Biocon-Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-3: Dr. Reddy’s Laboratories – Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-4: Lupin Limited- Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-5: Aurobindo Pharma Limited – Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-6: Wockhardt- Revenue by Business Segment (Billion US$), 2013 & 2014
Table 9-7: Zydus Cadila- Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-8: Glenmark- Revenues by Business Segment (Billion US$), 2013 & 2014
Table 9-9: Jubilant LifeSciences- Revenues by Business Segment (Billion US$), 2013 & 2014



【レポートのキーワード】

API(医薬品有効成分)、インド

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ インドのAPI(医薬品有効成分)市場機会(Opportunities in Indian API Market)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆